PATENT CLAIM ANALYSIS

Application Number: 16418794
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["424", "093200"]

Abstract:
The inventive technology relates to novel paratransgenic strategies for the control of pathogens. The inventive technology may specifically include a novel paratransgenic system configured to deliver one or more inhibitory RNA molecules to pathogen/disease-transmitting organisms. In a preferred embodiment, the invention may include one or more genetically engineered enteric bacteria configured to deliver one or more interfering RNA molecules to pathogen/disease-transmitting mosquitos.

Claim (Index 137):
The system of  claim 133 , wherein the genetically modified symbiotic bacteria is selected from the group consisting of: at least one biotyped mosquito symbiont identified as Ae001-263, an autotropic symbiotic enteric bacteria, an RNase III deficient symbiotic enteric bacteria,  E. coli  strain HT115,  E. coli  strain HT27,  E. coli  strain JC8031,  Pantoea  strain Ael6,  Serratia  strain AeS1, and  Serratia  strain MS5.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 100.0
- Lexical Diversity: 1.65
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15922904', '15709890', '15601446', '15507332', '13545604']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6633238323254835
- 35 USC 102 Novelty (BERT): 0.6516990265610156
- Combined Prediction Score: 0.6621613517490368
- Mean Citation Score: 351.70745
- Max Citation Score: 761.12585
- Similarity Product: 571.1799191392541

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test